Complete remission induction with combined VBMCP chemotherapy and interferon (rIFNα2b) in patients with multiple myeloma

Martin M. Oken, Robert A. Kyle, Philip R. Greipp, Neil E. Kay, Anastasios Tsiatis, Stephanie A. Gregory, Robert J. Spiegel, Michael J. O'connell

Research output: Contribution to journalArticle

19 Scopus citations

Abstract

The purpose of this study was to evaluate a new regimen for the treatment of multiple myeloma based on alternating 3-week cycles of chemotherapy and interferon (rIFNα2). In this prospective phase II clinical trial the Eastern Cooperative Oncology Group evaluated a regimen consisting of 2 cycles of VBMCP (Vincristine 1.2 mg/M2 IV d1, BCNU 20 mg/M2 IV dl, Melphalan 8 mg/M2 PO d1-4, Cyclophosphamide 400 mg/M2 IV d1, Prednisone 40 mg/M2 PO d1-7) followed by alternating 3-week cycles of VBMCP and rIFNα2 5Mu/M2 SC 3x/week. Treatment was administered for 2 years. Fifty-eight patients with previously untreated multiple myeloma were entered. Objective response (OR) required 50% decrease in M-protein with correction of severe anemia and no progression of skelet al disease. Complete remission (CR) was defined by disappearance of M-protein and normalization of the bone marrow morphology. Life table analysis was utilized to express survival and response duration. Fifty-four patients were evaluable. Objective response was seen in 80% of patients including CR in 30% (16 patients). The median response duration is 35 months, 46 months for patients with CR. The median survival is 42 months for all patients. Five year survival is 42%. Although 78% of patients had neutrophil nadirs <1000 × 109/L, the incidence of severe infection was only 9%. These data demonstrate that VBMCP + interferon is an effective new regimen combining chemotherapy with a biological response modifier for the treatment of multiple myeloma. The incidence of CR is high, and the response and survival durations appear to be I year longer than usually seen with standard chemotherapy. A current ECOG randomized trial compares VBMCP + interferon with VBMCP alone.

Original languageEnglish (US)
Pages (from-to)447-452
Number of pages6
JournalLeukemia and Lymphoma
Volume20
Issue number42130
DOIs
StatePublished - Jan 1 1996

Keywords

  • VBMCP
  • chemotherapy
  • complete remission
  • induction
  • interferon alpha
  • myeloma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN<sub>α2b</sub>) in patients with multiple myeloma'. Together they form a unique fingerprint.

  • Cite this

    Oken, M. M., Kyle, R. A., Greipp, P. R., Kay, N. E., Tsiatis, A., Gregory, S. A., Spiegel, R. J., & O'connell, M. J. (1996). Complete remission induction with combined VBMCP chemotherapy and interferon (rIFNα2b) in patients with multiple myeloma. Leukemia and Lymphoma, 20(42130), 447-452. https://doi.org/10.3109/10428199609052427